Sugi Predict

Sugi Predict / Targets / FUCA1

FUCA1

Tissue alpha-L-fucosidase · P04066 · FUCA1 on Sugi Atlas →

15,052 patent compounds predicted against FUCA1, 6,536 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1517549 SCHEMBL1517549 0.47 9/20
SCHEMBL1437889 SCHEMBL1437889 0.37 9/20
SCHEMBL1573174 SCHEMBL1573174 0.37 9/20
SCHEMBL1650553 SCHEMBL1650553 1.00 8/20
SCHEMBL1680180 SCHEMBL1680180 1.00 8/20
SCHEMBL917902 SCHEMBL917902 0.36 8/20
Nojirimycin Nojirimycin (SCHEMBL140917) 0.74 7/20
Scyllitol Scyllitol (SCHEMBL581992) 0.43 7/20
SCHEMBL1081023 SCHEMBL1081023 0.35 7/20
SCHEMBL1527010 SCHEMBL1527010 0.45 6/20
SCHEMBL564916 SCHEMBL564916 0.38 6/20
Deoxyfuconojirimycin Deoxyfuconojirimycin (SCHEMBL466591) 1.00 5/20
SCHEMBL1469250 SCHEMBL1469250 1.00 5/20
SCHEMBL1479404 SCHEMBL1479404 1.00 5/20
Deoxyfuconojirimycin Deoxyfuconojirimycin (SCHEMBL1867289) 1.00 5/20
SCHEMBL1879685 SCHEMBL1879685 1.00 5/20
SCHEMBL466573 SCHEMBL466573 0.93 5/20
SCHEMBL466574 SCHEMBL466574 0.93 5/20
SCHEMBL941276 SCHEMBL941276 0.44 5/20
SCHEMBL942167 SCHEMBL942167 0.44 5/20

Clinical trials — most relevant to FUCA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease PHASE4COMPLETED
High Dose or High Dose Frequency Study of Alglucosidase Alfa PHASE4COMPLETED
Stem Cell Transplant for Inborn Errors of Metabolism PHASE2/PHASE3COMPLETED
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease PHASE3COMPLETED
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) PHASE3COMPLETED
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa PHASE3ACTIVE_NOT_RECRUITING
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease PHASE3COMPLETED
An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) PHASE1/PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Vaccine Treatment for Surgically Resected Pancreatic Cancer PHASE1/PHASE2COMPLETED
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers PHASE1COMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Histoblood Group Antigens as a Risk Factor of Asthma nanCOMPLETED
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease nanAPPROVED_FOR_MARKETING
Longitudinal Studies of the Glycoproteinoses nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
Biomarker for Farber Disease (BioFarber) nanWITHDRAWN
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain nanCOMPLETED
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score nanACTIVE_NOT_RECRUITING
Mucin Glycosylating Enzymes in Head and Neck Cancers nanUNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes nanCOMPLETED
Assessment of Neurological Manifestations in Gaucher Disease Patients nanUNKNOWN
Dexmedetomidine and Propofol in Mechanically Ventilated Patients by Using Salivary Alpha-amylase as a Stress Marker nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis nanRECRUITING
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a FUCA1 binder may also engage these)

ProteinNameSimilarity
P17164 — 1.000 P17164 →
Q60HF8 — 1.000 Q60HF8 →
Q2KIM0 — 1.000 Q2KIM0 →
P48300 — 0.997 P48300 →
Q99LJ1 — 0.996 Q99LJ1 →
Q99KR8 — 0.994 Q99KR8 →
C3YWU0 — 0.993 C3YWU0 →
FUCA2 Plasma alpha-L-fucosidase 0.990 landscape →
Q6AYS4 — 0.989 Q6AYS4 →
Q5RFI5 — 0.989 Q5RFI5 →
GAA Lysosomal alpha-glucosidase 0.984 landscape →
Q58DH9 — 0.984 Q58DH9 →
P70699 — 0.983 P70699 →
Q9VTJ4 — 0.983 Q9VTJ4 →
P51569 — 0.983 P51569 →
GLA Alpha-galactosidase A 0.982 landscape →
Q9QWR8 — 0.981 Q9QWR8 →
O97524 — 0.981 O97524 →
Q8K2I4 — 0.981 Q8K2I4 →
Q8BHN3 — 0.981 Q8BHN3 →
Q5R5N6 — 0.981 Q5R5N6 →
O35632 — 0.981 O35632 →
Q90744 — 0.980 Q90744 →
DPEP1 Dipeptidase 1 0.979 landscape →
Q9MYM4 — 0.979 Q9MYM4 →
P31428 — 0.979 P31428 →
Q4FAT7 — 0.979 Q4FAT7 →
O77695 — 0.979 O77695 →
P22412 — 0.979 P22412 →
Q3SZM7 — 0.979 Q3SZM7 →